Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.

Expert Opin Drug Metab Toxicol

Millennium Pharmaceutics, Inc., DMPK, 45 Sidney St., Cambridge, MA 02139, USA.

Published: December 2005

Breast cancer resistance protein (BCRP), also known as ABCG2, ABCP and MXR, is a member of the ATP-binding cassette transporter G family. BCRP functions as a biological barrier that extrudes xenobiotics out of cells. The broad substrate specificity and tissue distributions of BCRP in the body make this transporter one of the major efflux transporters in chemotherapy. Recent studies have demonstrated that BCRP exerts a great impact on drug absorption and disposition. This review focuses on the role of BCRP in pharmacokinetics as well as in vitro and in vivo strategies to evaluate hepatic/intestinal BCRP-mediated drug transports and drug-drug interactions. The impacts of polymorphism and gender difference of BCRP are also discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.1.4.595DOI Listing

Publication Analysis

Top Keywords

breast cancer
8
cancer resistance
8
resistance protein
8
drug-drug interactions
8
bcrp
6
protein pharmacokinetics
4
pharmacokinetics drug-drug
4
interactions breast
4
protein bcrp
4
bcrp abcg2
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!